Search | Clinical Trials Finder

Conditions: Contraception
Interventions: Mirena (levonorgestrel-releasing intrauterine system); Device
Lead sponsor: University of Louisville; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Endometrial Hyperplasia
Interventions: BAY865028, Medroxyprogesterone acetate; Combination Product · Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more

Conditions: Ovarian Suppression
Interventions: Low dose formulation, High dose formulation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometriosis
Interventions: norethindrone acetate (NETA), Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 24 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more

Conditions: Emergency Contraception
Interventions: Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg, Etonogestrel implant with oral placebo; Drug · Device
Lead sponsor: Lori Gawron; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Endometrial Hyperplasia, Grade 1 Endometrial Cancer
Interventions: Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.; Behavioral · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Albuquerque, New Mexico • Oklahoma City, Oklahoma

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Hemostasis, Oral Contraceptive
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more

Conditions: Complex Atypical Hyperplasia, Endometrial Cancer
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Cincinnati, Ohio

Conditions: Contraception
Interventions: Diazepam, Lidocaine, Placebo pill, Placebo injection; Drug · Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Contraceptive Usage
Interventions: Levonorgestrel IUD; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Contraception
Interventions: Paragard, Mirena; Device · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Contraception
Interventions: IUD insertion, Povidone-Iodine, Chlorhexidine, Oxygen, Nitrous oxide; Procedure · Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 12 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Vaginal Bleeding
Interventions: Intrauterine system; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Morristown, New Jersey • Newark, New Jersey

Conditions: Emergency Contraception
Interventions: DR-104; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 11 Years to 16 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: HIV Prevention
Interventions: 200 mg of DPV + 320 mg LNG, 200 mg of DPV; Combination Product
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions: TFV/LNG IVR, Placebo; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: HIV Infections, Contraception, Pharmacokinetics
Interventions: levonorgestrel, efavirenz; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Denver, Colorado • Providence, Rhode Island

Conditions: Healthy Participants
Interventions: Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Contraception
Interventions: IUD; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: La Jolla, California • San Diego, California • Chicago, Illinois + 1 more

Conditions: Contraception
Interventions: Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A); Device
Lead sponsor: University of Chicago; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Obesity, Oral Contraception, and Ovarian Suppression

IUD and Norethindrone Acetate for Treatment of Endometriosis

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo

Uterine Preservation Via Lifestyle Transformation

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing IUD

'Levonorgestrel IUD Insertion After D&E Procedure

Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study

Nitrous Oxide for Pain Management of Intrauterine Device (IUD) Insertion

Does Skyla Insertion Timing Impact Bleeding?

Emergency Contraception Actual Use Study

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

Early vs. Interval Postpartum IUD Insertion

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial